• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Novo slumps, Lilly gains on trial data results

by December 20, 2024
written by December 20, 2024

Investing.com — Shares of Novo Nordisk (NYSE:NVO) plummeted over 19% in premarket trading Friday after the results from its phase 3 trial of CagriSema, its next-generation obesity drug, disappointed.

Meanwhile, rival Eli Lilly (NYSE:LLY) surged more than 9%.

Novo Nordisk’s REDEFINE 1 trial showed that people treated with CagriSema, a combination of cagrilintide and semaglutide, achieved a weight loss of 22.7% after 68 weeks.

While statistically significant and superior to the results achieved with either drug alone, the weight loss fell short of the target of 25%.

“This was achieved even though only 57% of patients reached the highest CagriSema dose,” commented Martin Holst Lange, Novo Nordisk’s executive vice president for Development.

Lange highlighted the drug’s potential, noting the company’s plans to “further explore the additional weight loss potential of CagriSema.”

The trial involved 3,417 overweight or obese participants and evaluated the efficacy and safety of CagriSema. The trial achieved its primary endpoint by “demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo.”

While the results showed promise, the market reacted negatively to the below-expectation outcomes.

Conversely, the sharp rise in Eli Lilly’s stock reflects growing confidence in its competing obesity treatments.

The results from Novo’s second phase 3 trial, REDEFINE 2, in adults with type 2 diabetes and either obesity or overweight are expected during the first half of 2025.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Foxconn interest in Nissan on hold amid Honda merger talks, Bloomberg reports
next post
European stock markets retreat as Trump’s comments spark trade war concerns

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • Future of UN climate dialogue threatened by budget shortfall
    • UBS’s Lefkowitz says U.S. stock valuations are ‘reasonable’

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy